文献速递关节外科

滑液白细胞计数与分类不能单独作为假体周围感染确诊试验:对2025年Meta分析的方法学审计与再分析

Synovial Fluid Leukocyte Count and Differential Are Poor Standalone Rule-in Tests for Periprosthetic Joint Infection: Results of a Methodological Audit and Reanalysis of the 2025 Meta-analysis Underpinning the Unified Periprosthetic Joint Infection Criteria.
PubMed 文献 · Clin Orthop Relat Res · 2026-06-03

该研究对支持统一PJI标准的2025年Meta分析进行方法学审计,发现数据完整性错误、结局依赖性阈值选择等关键缺陷,AMSTAR-2评级为极低置信度。对同一74项研究的再分析显示,滑液白细胞计数和中性粒细胞百分比的汇总特异度分别为90%和92%,在20%患病率下阳性预测值仅67%和73%,异质性高,不能作为独立确诊试验。

要点

  • 滑液WBC>3000 cells/µL或PMN>75%不应单独用于确诊PJI。
  • 2025年Meta分析存在数据列错位、结局依赖性阈值选择等关键缺陷。
  • 再分析显示两项试验特异度异质性高,阳性预测值低,约1/3阳性为假阳性。

核心结论

  • 滑液白细胞计数和中性粒细胞百分比是较差的独立确诊试验,不应单独用于确诊PJI。

研究设计与样本

  • 独立联盟对2025年Meta分析及其74项原始研究进行方法学再评估,使用AMSTAR-2和Cochrane诊断准确性手册审计,并用分层双变量随机效应模型再分析。

主要发现

  • AMSTAR-2评级为极低置信度,审计发现三项关键局限:数据完整性错误(假阳性与假阴性计数列错位)、结局依赖性阈值选择、高异质性下仍给出汇总估计。
  • 再分析中WBC和PMN的特异度异质性仍高(I²=85%和93%),汇总特异度分别为90%(95%CI 86%–92%)和92%(95%CI 87%–96%)。
  • 在20%PJI患病率下,WBC和PMN的阳性预测值分别为67%(95%CI 61%–74%)和73%(95%CI 63%–87%)。

关键数值与推荐

  • 独立确诊试验的充分性能 pragmatically 定义为在临床合理患病率下阳性预测值>90%,可推广性定义为特异度跨机构一致性。
  • 再分析仅纳入预设阈值的研究,使用分层双变量随机效应模型。

临床怎么用

  • 外科医生不应将滑液WBC计数或PMN百分比阈值作为PJI的独立确诊标准。
  • 这些试验应作为多模式诊断框架中的支持性发现,尤其当结果与临床、培养、组织学、血清标志物或其他滑液检测不一致时。
  • 专业组织和监管机构应重新考虑推荐WBC或PMN作为独立确诊试验,直至有方法学稳健的证据显示可重复阈值且阳性预测值足够高。

局限性

  • 原文未报告再分析的其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Unified Periprosthetic Joint Infection (PJI) Criteria were developed and endorsed by the European Society of Clinical Microbiology and Infectious Diseases, the European Bone and Joint Infection Society, the Infectious Diseases Society of America, and the Musculoskeletal Infection Society and formally presented at the 2025 International Consensus Meeting. These criteria recommended that synovial fluid white blood cells (WBC) > 3000 cells/µL or polymorphonuclear cells (PMN) > 75% each should be considered individually sufficient to confirm a diagnosis of PJI as standalone rule-in tests, stating specificity of > 95%. These thresholds and performance align with a 2025 meta-analysis published on behalf of the Unified PJI Definition Task Force, reporting specificities of 98.5% and 97.8%, respectively. Because such near-perfect specificities conflict with prior meta-analyses and known causes of false-positive leukocyte testing, independent validation of the supporting evidence is warranted. QUESTIONS/PURPOSES: (1) Is the 2025 meta-analysis published on behalf of the Unified PJI Definition Task Force methodologically rigorous and reproducible under independent appraisal and audit? (2) Do WBC count and PMN percentage demonstrate sufficient and generalizable rule-in performance for PJI? METHODS: An independent consortium with expertise in PJI diagnostics, epidemiology, and biostatistics conducted a formal methodological reappraisal of the 2025 meta-analysis. To address the first study question, the 2025 meta-analysis, all 74 primary studies, and the original source data files provided by that study's authors were assessed. After reproducing the original results of the 2025 meta-analysis to confirm understanding of data files and workflow, two independent reviewers used A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) to assess quality, and then a methodological audit was performed using the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Limitations were graded by consensus as critical, major, or minor, with critical limitations independently verified by three statisticians and two clinicians. To address our second study question, a reanalysis of the same corpus of 74 studies was performed using a hierarchical bivariate random-effects model, restricted to studies with predetermined thresholds. A standalone rule-in test is one in which a positive result alone is sufficient to establish the diagnosis of PJI, and its performance is most appropriately assessed using positive predictive value (PPV), which directly reflects the probability that a positive result represents true PJI. Sufficient rule-in performance was pragmatically defined as a PPV of > 90% across clinically plausible prevalence rates. Sufficiently generalizable performance was defined as demonstrable consistency across institutions, assessed through between-study heterogeneity of specificity. RESULTS: For the first study question, AMSTAR-2 assessment rated the 2025 meta-analysis as critically low overall confidence, reflecting weaknesses in multiple domains. Three critical limitations were identified during audit: (1) a data integrity discrepancy in the software input table used for the 2025 meta-analysis, in which false-positive counts were placed in the false-negative column and false-negative counts were placed in the false-positive column for all studies, rendering downstream results unreliable; (2) an outcome-dependent (self-fulfilling) threshold-selection approach that included only studies already reporting > 95% sensitivity or specificity, yielding results that were mathematically constrained to meet the 95% performance criteria, followed by derivation of thresholds using unweighted medians rather than meta-analytic techniques; and (3) presentation of pooled estimates and clinical threshold recommendations despite acknowledgment of markedly high heterogeneity (I 2 statistic 88.3% to 99.3%). Major limitations included unit-of-analysis errors, use of specificity alone (rather than PPV) to define rule-in performance, unaddressed incorporation bias, and reliance on data-driven (Youden index) threshold selection. Regarding our second study question, in a reanalysis of the same 74 source studies, we found that WBC count and PMN percentage did not demonstrate sufficient or generalizable rule-in performance for PJI. Specifically, the heterogeneity for specificity remained high (I 2 = 85% for WBC and I 2 = 93% for PMN), reflecting considerable between-study variability. Summary specificity was 90% (95% confidence interval [CI] 86% to 92%) for WBC and 92% (95% CI 87% to 96%) for PMN. Resulting PPVs were low across clinically plausible disease prevalence rates, with point estimates of 67% (95% CI 61% to 74%) and 73% (95% CI 63% to 87%), respectively, at 20% PJI prevalence. CONCLUSION: Critical data integrity discrepancies and methodological limitations substantially undermine the reliability of the 2025 meta-analysis published on behalf of the Unified PJI Definition Task Force. Reanalysis of the same evidence base using recommended meta-analytic methods characterizes WBC count and PMN percentage as poor standalone rule-in tests for PJI for two main reasons: (1) the high heterogeneity of specificity for both WBC count and PMN percentage undermines the generalizability of these tests across institutions and precludes the establishment of universal thresholds, and (2) PPVs at clinically reasonable prevalence rates were low (67% to 73%) for standalone rule-in test usage, meaning that roughly 1 in 3 positive results would likely be a false-positive. CLINICAL RELEVANCE: We recommend that surgeons not use synovial fluid WBC count or PMN percentage thresholds as standalone rule-in criteria for PJI. Instead, these tests should be interpreted as supportive findings within a multimodal diagnostic framework, particularly when results are discordant with clinical findings, cultures, histology, serum markers, or other synovial tests. Professional organizations and regulatory bodies should reconsider recommending WBC count or PMN percentage as standalone rule-in tests for PJI until methodologically robust evidence demonstrates reproducible thresholds with sufficiently high PPVs.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Parthasarathi A, Setoguchi S, DeConti DK, et al. Synovial Fluid Leukocyte Count and Differential Are Poor Standalone Rule-in Tests for Periprosthetic Joint Infection: Results of a Methodological Audit and Reanalysis of the 2025 Meta-analysis Underpinning the Unified Periprosthetic Joint Infection Criteria. Clin Orthop Relat Res. 2026. PMID: 42233696. doi:10.1097/CORR.0000000000004002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。